TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Neurosense Therapeutics Ltd. ( (NRSN) ) has shared an announcement.
NeuroSense Therapeutics Ltd. has announced its upcoming Annual General Meeting of Shareholders, scheduled for September 25, 2025, in Herzliya, Israel. The meeting will address the appointment of auditors, election and re-election of board members, and other potential matters. This meeting is crucial for stakeholders as it will shape the company’s governance and strategic direction for the upcoming year.
The most recent analyst rating on (NRSN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.
Spark’s Take on NRSN Stock
According to Spark, TipRanks’ AI Analyst, NRSN is a Underperform.
Neurosense Therapeutics Ltd. faces substantial financial difficulties, including no revenue and negative equity, severely impacting its overall score. Technical indicators are neutral but do not offset financial weaknesses. The valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on NRSN stock, click here.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. operates within the biotechnology industry, focusing on the development of treatments for neurodegenerative diseases. The company is headquartered in Herzliya, Israel, and is involved in creating innovative therapies to address unmet medical needs in its market.
Average Trading Volume: 361,227
Technical Sentiment Signal: Sell
Current Market Cap: $28.54M
Learn more about NRSN stock on TipRanks’ Stock Analysis page.